secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-03-14T23:59:59+00:00
Accession:  0001737287-24-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene reports Q4 net loss $85.8M, cash $448.7M; ALPHA3 trial to start mid-2024
--------------------------------------------------------------------------------

- Net loss Q4 2023 $85.8M ($0.51/share); full-year net loss $327.3M ($2.09/share).
- Cash, cash equivalents & investments $448.7M as of Dec 31, 2023; cash runway into 2026 reaffirmed.
- 2024 GAAP op. expenses ~$280M; expected cash burn ~$190M; non-cash comp ~$60M.
- Pivotal cema-cel ALPHA3 1L LBCL trial enrollment begins mid-2024; randomized 230 MRD+ patients.
- ALLO-329 (CD19 Dagger) for autoimmune disease to enter Phase 1 in early 2025; Arbor Biotechnologies licensing deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000019/0001737287-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000019/allo-20240314.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer